1. PRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
- Author
-
Schmidt, Christin, Cohen, Sarah, Gudenas, Brian L, Husain, Sarah, Carlson, Annika, Westelman, Samantha, Wang, Linyu, Phillips, Joanna J, Northcott, Paul A, Weiss, William A, and Schwer, Bjoern
- Subjects
Biochemistry and Cell Biology ,Biomedical and Clinical Sciences ,Biological Sciences ,Pediatric ,Stem Cell Research - Nonembryonic - Human ,Human Genome ,Stem Cell Research - Nonembryonic - Non-Human ,Brain Disorders ,Brain Cancer ,Pediatric Cancer ,Rare Diseases ,Genetics ,Stem Cell Research ,Neurosciences ,Cancer ,2.1 Biological and endogenous factors ,Generic health relevance ,Medulloblastoma ,Humans ,Chromatin ,Gene Expression Regulation ,Neoplastic ,Cerebellar Neoplasms ,Histone-Lysine N-Methyltransferase ,Cell Line ,Tumor ,Neuroepithelial Cells ,Animals ,Histones - Abstract
SNCAIP duplication may promote Group 4 medulloblastoma via induction of PRDM6, a poorly characterized member of the PRDF1 and RIZ1 homology domain-containing (PRDM) family of transcription factors. Here, we investigated the function of PRDM6 in human hindbrain neuroepithelial stem cells and tested PRDM6 as a driver of Group 4 medulloblastoma. We report that human PRDM6 localizes predominantly to the nucleus, where it causes widespread repression of chromatin accessibility and complex alterations of gene expression patterns. Genome-wide mapping of PRDM6 binding reveals that PRDM6 binds to chromatin regions marked by histone H3 lysine 27 trimethylation that are located within, or proximal to, genes. Moreover, we show that PRDM6 expression in neuroepithelial stem cells promotes medulloblastoma. Surprisingly, medulloblastomas derived from PRDM6-expressing neuroepithelial stem cells match human Group 3, but not Group 4, medulloblastoma. We conclude that PRDM6 expression has oncogenic potential but is insufficient to drive Group 4 medulloblastoma from neuroepithelial stem cells. We propose that both PRDM6 and additional factors, such as specific cell-of-origin features, are required for Group 4 medulloblastoma. Given the lack of PRDM6 expression in normal tissues and its oncogenic potential shown here, we suggest that PRDM6 inhibition may have therapeutic value in PRDM6-expressing medulloblastomas.
- Published
- 2024